Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Chemocentryx
Chemocentryx
(CCXI)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Tavneos
Avacopan
2021-10-07
2029-2041
Anti-neutrophil cytoplasmic antibody-associated vasculitis
,
Microscopic polyangiitis
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Avacopan
electrocardiography
,
liver diseases
,
hepatic insufficiency
,
systemic lupus erythematosus
,
healthy volunteers/patients
,
chronic kidney failure
,
kidney diseases
,
iga glomerulonephritis
,
glomerulonephritis
,
hidradenitis suppurativa
,
hidradenitis
,
hemolytic-uremic syndrome
,
hemolysis
,
syndrome
,
atypical hemolytic uremic syndrome
,
azotemia
,
vasculitis
,
anti-neutrophil cytoplasmic antibody-associated vasculitis
,
granulomatosis with polyangiitis
,
microscopic polyangiitis
,
systemic vasculitis
Albumin
pancreatic neoplasms
,
adenocarcinoma
ILACIRNON
type 2 diabetes mellitus
,
diabetes mellitus
,
focal segmental glomerulosclerosis
,
diabetic nephropathies
,
nephrotic syndrome
,
nephrosis
,
kidney diseases
,
albuminuria
Vercirnon
ulcerative colitis
,
colitis
,
ulcer
,
celiac disease
,
crohn disease
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use